Related Experiment Videos
Pediatric liver transplantation
1Department of Child Health, King's College Hospital, Denmark Hill, London, UK. anil.dhawan@kcl.ac.uk
Insights
Pediatric liver transplantation has advanced significantly, improving survival rates due to cyclosporin and surgical innovations like living related donation. Despite ongoing immunosuppression concerns, most children achieve a good quality of life.
Area of Science:
- Pediatric Hepatology
- Transplant Surgery
- Immunology
Background:
- Liver transplantation is a primary treatment for end-stage liver disease in children.
- Significant improvements in graft and patient survival have been observed over the past 20 years.
- Cyclosporin availability is a key factor in enhanced survival rates.
Purpose of the Study:
- To review the advancements in pediatric liver transplantation.
- To discuss the impact of surgical innovations and immunosuppression on outcomes.
- To highlight the current challenges and quality of life in pediatric transplant recipients.
Main Methods:
- Review of recent literature on pediatric liver transplantation.
- Analysis of survival data and complications associated with immunosuppression.
- Evaluation of surgical techniques including living related donation and auxiliary transplantation.
Main Results:
- Improved graft and patient survival rates in the last two decades.
- Cyclosporin identified as a major contributor to improved outcomes.
- Living related donation expanded donor pool and accessibility.
- Auxiliary liver transplantation offers benefits for metabolic disorders and acute liver failure.
- Nephrotoxicity, lymphoproliferative disease, and viral infections remain significant concerns.
Conclusions:
- Pediatric liver transplantation is a successful treatment for end-stage liver disease.
- Continued research is needed to mitigate immunosuppression complications.
- Most children with successful grafts experience a near-normal quality of life.
Abstract:
Liver transplantation in children has become a treatment of choice for end-stage liver disease. Both graft and patient survival has significantly improved over the last two decades. The major factor contributing towards improved survival is availability of cyclosporin. Surgical innovations like living related donation has not only increased the donor pool, but has also helped patients in countries where cadaveric donation is not available. Auxiliary liver transplantation has made a significant change to the management of children with liver-based metabolic disorders and, in selected cases of acute liver failure, immunosuppression can be safely withdrawn once the native liver recovers. However, the complications associated with immunosuppression, such as nephrotoxicity, lymphoproliferative disease and viral infections, continue to be a matter of great concern. Most children with good graft function enjoy near normal quality of life.